GlassScriptPhysician profile
Efat Azizi
NPI 1255580783
$22,154.81
in general payments reported to CMS, 2019-2025
27 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,350 · 2020: $2,116 · 2021: $2,308 · 2022: $629 · 2023: $6,106 · 2024: $1,333 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,180 · Honoraria: $1,759 · Travel and Lodging: $1,421 · Food and Beverage: $1,323 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,180.00 |
| Honoraria | $1,759.36 |
| Travel and Lodging | $1,420.71 |
| Food and Beverage | $1,323.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $4,010.77 | 2019 | |
| Exelixis INC. | $3,843.52 | 2019 | |
| Pharmacosmos Therapeutics INC. | $2,839.11 | 2023 | Monoferric |
| Janssen Biotech, INC. | $2,400.00 | 2023 | Tecvayli, Darzalex, Carvykti |
| Glaxosmithkline, LLC. | $1,983.58 | 2020-2025 | Jemperli |
| Astrazeneca Pharmaceuticals LP | $1,702.34 | 2020-2025 | Imfinzi |
| Gilead Sciences, INC. | $1,337.21 | 2021-2025 | Trodelvy |
| Pfizer INC. | $1,116.13 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $935.26 | 2020-2022 | |
| Incyte Corporation | $291.57 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $271.49 | 2025 | Xpovio |
| Genzyme Corporation | $211.17 | 2024-2025 | |
| Sirtex Medical INC | $176.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $128.71 | 2019-2025 | Keytruda |
| Stemline Therapeutics INC. | $125.00 | 2024 | Orserdu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $124.50 | 2021 | |
| Lilly USA, LLC | $116.98 | 2019 | |
| Novocure INC. | $106.14 | 2025 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $96.66 | 2023 | |
| Global Blood Therapeutics, INC. | $91.02 | 2021 | |
| Adaptive Biotechnologies Corporation | $90.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.74 | 2025 | |
| Kite Pharma, INC. | $38.85 | 2021 | |
| Alexion Pharmaceuticals, INC. | $33.13 | 2021 | |
| Astellas Pharma US INC | $14.93 | 2022 | |
| Veracyte, INC. | $13.01 | 2022 | |
| Myriad Genetic Laboratories, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efat Azizi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.